{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-073372","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2024-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.228067+00:00","generated_at":"2026-06-01T03:47:54.815109+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Regeneron shareholders elect directors, approve executive compensation at 2024 annual meeting","bullets":["Class III directors elected: N.A. Coles, K. Guarini, A.F. Ryan, G.L. Sing; Class II director D.P. Schenkein elected.","Ratification of PwC as auditor for FY2024: 111.4M for, 5.3M against, 60.6K abstain.","Advisory vote on executive compensation passed: 106.7M for, 5.6M against, 207.5K abstain, 4.2M broker non-votes.","Non-binding shareholder proposal requesting simple majority voting approved: 85.9M for, 26.4M against, 188.7K abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-073372","json":"https://secwatch.observer/filing/0001104659-24-073372.json","markdown":"https://secwatch.observer/filing/0001104659-24-073372.md","text":"https://secwatch.observer/filing/0001104659-24-073372.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000110465924073372/0001104659-24-073372-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000110465924073372/tm2417559d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T03:47:54.815109+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}